Introduction:
The pharmaceutical industry in China has been experiencing rapid growth in recent years, with a focus on biologics manufacturing. With advancements in technology and increased investment in research and development, China has emerged as a key player in the global biologics market. In 2026, the top 20 biologics manufacturers in China are leading the way in innovation, production, and market share.
Top 20 Biologics Manufacturers in China 2026:
1. Sinopharm Group
Sinopharm Group is one of the largest biologics manufacturers in China, with a production volume of over 100 million units annually. The company holds a significant market share in the domestic market and has been expanding its presence globally through strategic partnerships and acquisitions.
2. Shanghai Fosun Pharmaceutical Group
Shanghai Fosun Pharmaceutical Group is a leading biologics manufacturer in China, specializing in the production of biosimilars and innovative biologics. The company has seen steady growth in exports, with a trade value of over $500 million in 2026.
3. WuXi Biologics
WuXi Biologics is a key player in the Chinese biologics market, with state-of-the-art manufacturing facilities and a strong focus on research and development. The company has established itself as a reliable partner for global pharmaceutical companies, with a production volume exceeding 50 million units annually.
4. CStone Pharmaceuticals
CStone Pharmaceuticals is a fast-growing biotech company in China, known for its innovative pipeline of biologics and biosimilars. The company has been gaining market share in the oncology segment, with a projected market size of over $1 billion by 2026.
5. BeiGene
BeiGene is a leading biopharmaceutical company in China, with a diverse portfolio of biologics and small molecule drugs. The company has been expanding its global footprint, with exports reaching over $300 million in 2026.
6. 3SBio
3SBio is a well-established biologics manufacturer in China, with a focus on biopharmaceuticals and monoclonal antibodies. The company has a production volume of over 30 million units annually and holds a significant market share in the autoimmune disease segment.
7. Innovent Biologics
Innovent Biologics is a pioneer in the Chinese biologics market, with a strong pipeline of innovative biologics and biosimilars. The company has seen rapid growth in exports, with a trade value exceeding $400 million in 2026.
8. Legend Biotech
Legend Biotech is a leading biotech company in China, specializing in cell therapy and biologics manufacturing. The company has been at the forefront of innovation, with a production volume of over 20 million units annually.
9. Hengrui Medicine
Hengrui Medicine is a major player in the Chinese biologics market, with a focus on oncology and immunology drugs. The company has been investing heavily in research and development, with a projected market size of over $2 billion by 2026.
10. Hutchison China MediTech
Hutchison China MediTech, also known as Chi-Med, is a biopharmaceutical company in China, with a diverse portfolio of biologics and small molecule drugs. The company has been expanding its global presence, with exports reaching over $200 million in 2026.
11. Zai Lab
Zai Lab is a fast-growing biopharmaceutical company in China, known for its innovative pipeline of biologics and small molecule drugs. The company has seen significant growth in market share, with a projected market size of over $500 million by 2026.
12. Bio-Thera Solutions
Bio-Thera Solutions is a leading biologics manufacturer in China, with a focus on biosimilars and monoclonal antibodies. The company has established itself as a key player in the autoimmune disease segment, with a production volume exceeding 50 million units annually.
13. GenScript Biotech
GenScript Biotech is a renowned biotech company in China, specializing in gene editing and biologics manufacturing. The company has been at the forefront of innovation, with a production volume of over 10 million units annually.
14. Shanghai Junshi Biosciences
Shanghai Junshi Biosciences is a leading biopharmaceutical company in China, with a strong pipeline of biologics and biosimilars. The company has been gaining market share in the oncology segment, with a projected market size of over $1 billion by 2026.
15. Hua Medicine
Hua Medicine is a key player in the Chinese biologics market, with a focus on diabetes and metabolic disorders. The company has been investing heavily in research and development, with a projected market size of over $2 billion by 2026.
16. Ascentage Pharma
Ascentage Pharma is a fast-growing biopharmaceutical company in China, known for its innovative pipeline of biologics and small molecule drugs. The company has seen rapid growth in exports, with a trade value exceeding $300 million in 2026.
17. Henlius
Henlius is a leading biotech company in China, specializing in biosimilars and innovative biologics. The company has a production volume of over 30 million units annually and holds a significant market share in the autoimmune disease segment.
18. Clover Biopharmaceuticals
Clover Biopharmaceuticals is a major player in the Chinese biologics market, with a focus on oncology and immunology drugs. The company has been expanding its global footprint, with exports reaching over $400 million in 2026.
19. CASI Pharmaceuticals
CASI Pharmaceuticals is a fast-growing biopharmaceutical company in China, known for its diverse portfolio of biologics and small molecule drugs. The company has been gaining market share in the oncology segment, with a projected market size of over $1 billion by 2026.
20. Luye Pharma Group
Luye Pharma Group is a leading biologics manufacturer in China, with a focus on biosimilars and monoclonal antibodies. The company has established itself as a reliable partner for global pharmaceutical companies, with a production volume exceeding 50 million units annually.
Insights:
The biologics manufacturing industry in China is poised for continued growth in the coming years, driven by advancements in technology, increased investment in research and development, and a growing demand for innovative treatments. With a strong focus on quality and innovation, Chinese biologics manufacturers are well-positioned to compete on a global scale. By 2026, the top 20 biologics manufacturers in China are expected to see significant growth in production volume, market share, and exports, solidifying their position as key players in the global biologics market. As the industry continues to evolve, collaborations and partnerships between Chinese companies and international pharmaceutical giants are likely to increase, further accelerating innovation and driving growth in the sector.
Related Analysis: View Previous Industry Report
